Castle Biosciences (CSTL) on Sunday reported data from studies backing the "clinical utility" of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding treatment paths in patients with scan cancer.
The treatment options include sentinel lymph node biopsy for patients with melanoma and surveillance imaging for those with squamous cell carcinoma of the skin.
Etan Marks, a pathologist and author of one of the studies, said they showed the Castle Biosciences tests provide physicians and patients insights that "enhance clinical decision-making and arm clinicians with more precise risk information to help route patients to the most appropriate modality aligned to their risk of metastasis and survival."
The company said the gene expression profiling and risk stratification tests show which patients are at lower risk and able to forgo certain tests.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。